The MErCuRIC Phase I trial was presented at the ESMO 2016 Congress in Copenhagen (7 – 11 Oct 2016).

MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours (Poster: 480P)

R. Wilson, M. Middleton, J. Houlden, S. Van Schaeybroeck, C. Rolfo, E. Elez, J. Taieb , T. André, A. Bardelli , P. Laurent-Puig, J. Tabernero, M. Peeters, T. Maughan, C. Roberts, S. Love, M. Lawler , M. Salto-Tellez, M. Grayson, V. Popovici, F. Di Nicolantonio